Detecting muscle loss in patients with ovarian or endometrial cancer
Prospective Monocentric Study of the Detection of Sarcopenia in Clinical Practice in Patients With Ovarian or Endometrial Cancer Requiring Systemic Oncological Treatment
This study is testing how muscle loss affects treatment tolerance and survival in patients with ovarian or endometrial cancer by measuring their muscle mass and nutrition over a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Hospitalier Metropole Savoie Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chambéry, Savoie) |
| Trial ID | NCT05833321 on ClinicalTrials.gov |
What this trial studies
This prospective, non-randomized study aims to identify criteria correlated with sarcopenia in patients diagnosed with ovarian or endometrial cancer who require systemic oncological treatment. The study will measure muscle mass and other related parameters using the CT-X method at the L3 vertebra level, alongside various nutritional and physical assessments. Data will be collected at 6 and 12 months post-inclusion to evaluate the relationship between sarcopenia and treatment tolerance, progression-free survival, and overall survival.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of ovarian or endometrial cancer requiring chemotherapy.
Not a fit: Patients with ovarian or endometrial cancer who do not require chemotherapy or have other concurrent cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of sarcopenia in cancer patients, potentially enhancing treatment outcomes and quality of life.
How similar studies have performed: While the approach of assessing sarcopenia in cancer patients is gaining attention, this specific study's methodology is relatively novel and has not been extensively tested in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients at least 18 years old * Patient presenting with a diagnosis of cancer of ovarian origin with an indication for chemotherapy * Patient with a diagnosis of endometrial cancer with an indication for chemotherapy * Patient with no diagnosis of other types of cancer in the previous five years * Collection of consent * Patient affiliated to a Social Security scheme Exclusion Criteria: * Patient with cancer of ovarian origin not requiring chemotherapy treatment * Patient with endometrial cancer not requiring chemotherapy treatment * Discovery of an intercurrent cancer other than skin or cervix cancers. * Patient wearing a Pace maker
Where this trial is running
Chambéry, Savoie
- Centre Hospitalier Metropole Savoie — Chambéry, Savoie, France (Recruiting)
Study contacts
- Principal investigator: fillon aurélie — Centre Hospitalier Metropole Savoie
- Study coordinator: jego florence
- Email: florence.jego@ch-metropole-savoie.fr
- Phone: 0479965813
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.